Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Perucca, E; Dulac, O; Shorvon, S; Tomson, T
   Harnessing the clinical potential of antiepileptic drug therapy - Dosage optimisation
   CNS DRUGS
   
   E. Perucca et al., "Harnessing the clinical potential of antiepileptic drug therapy - Dosage optimisation", CNS DRUGS, 15(8), 2001, pp. 609-621
2. French, JA; Perucca, E; Richens, A
   Special issue: Design of clinical trials of antiepileptic drugs - Preface
   EPILEPSY RESEARCH
   
   J.A. French et al., "Special issue: Design of clinical trials of antiepileptic drugs - Preface", EPILEPSY R, 45(1-3), 2001, pp. 1-1
3. Perucca, E
   Trial duration and follow-up
   EPILEPSY RESEARCH
   
   E. Perucca, "Trial duration and follow-up", EPILEPSY R, 45(1-3), 2001, pp. 123-127
4. Perucca, E
   Discussion: Trials in women
   EPILEPSY RESEARCH
   
   E. Perucca, "Discussion: Trials in women", EPILEPSY R, 45(1-3), 2001, pp. 147-147
5. Perucca, E; Richens, A
   Trials in the elderly
   EPILEPSY RESEARCH
   
   E. Perucca e A. Richens, "Trials in the elderly", EPILEPSY R, 45(1-3), 2001, pp. 149-151
6. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
   Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
   EPILEPSY RESEARCH
   
   M. Bialer et al., "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)", EPILEPSY R, 43(1), 2001, pp. 11-58
7. Spina, E; Scordo, MG; Avenoso, A; Perucca, E
   Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity
   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
   
   E. Spina et al., "Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity", J CL PSYCH, 21(1), 2001, pp. 108-109
8. Battino, D; Croci, D; Granata, T; Mamoli, D; Messina, S; Perucca, E
   Single-dose pharmacokinetics of lamotrigine in children: Influence of age and antiepileptic comedication
   THERAPEUTIC DRUG MONITORING
   
   D. Battino et al., "Single-dose pharmacokinetics of lamotrigine in children: Influence of age and antiepileptic comedication", THER DRUG M, 23(3), 2001, pp. 217-222
9. Perucca, E
   The management of refractory idiopathic epilepsies
   EPILEPSIA
   
   E. Perucca, "The management of refractory idiopathic epilepsies", EPILEPSIA, 42, 2001, pp. 31-35
10. Genton, P; Guerrini, R; Perucca, E
    Tiagabine in clinical practice
    EPILEPSIA
    
    P. Genton et al., "Tiagabine in clinical practice", EPILEPSIA, 42, 2001, pp. 42-45
11. Spina, E; Avenoso, A; Facciola, G; Salemi, M; Scordo, MG; Ancione, M; Madia, AG; Perucca, E
    Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia
    PSYCHOPHARMACOLOGY
    
    E. Spina et al., "Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia", PSYCHOPHAR, 153(2), 2001, pp. 238-243
12. Gatti, G; Furlanut, M; Perucca, E
    Interindividual variability in the metabolism of anti-epileptic drugs and its clinical implications
    INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM
    
    G. Gatti et al., "Interindividual variability in the metabolism of anti-epileptic drugs and its clinical implications", INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 157-180
13. Furlanut, M; Wu, G; Perucca, E
    Variability in the metabolism of levodopa and clinical implications
    INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM
    
    M. Furlanut et al., "Variability in the metabolism of levodopa and clinical implications", INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 181-227
14. Volosov, A; Bialer, M; Sun, XD; Perucca, E; Sintov, A; Yagen, B
    Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine
    JOURNAL OF CHROMATOGRAPHY B
    
    A. Volosov et al., "Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine", J CHROMAT B, 738(2), 2000, pp. 419-425
15. Gatti, G; Bonomi, I; Jannuzzi, G; Perucca, E
    The new antiepileptic drugs: Pharmacological and clinical aspects
    CURRENT PHARMACEUTICAL DESIGN
    
    G. Gatti et al., "The new antiepileptic drugs: Pharmacological and clinical aspects", CUR PHARM D, 6(8), 2000, pp. 839-860
16. Schmidt, D; Gram, L; Brodie, M; Kramer, G; Perucca, E; Kalviainen, R; Elger, CE
    Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician
    EPILEPSY RESEARCH
    
    D. Schmidt et al., "Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician", EPILEPSY R, 41(3), 2000, pp. 245-251
17. Perucca, E; Beghi, E; Dulac, O; Shorvon, S; Tomson, T
    Assessing risk to benefit ratio in antiepileptic drug therapy
    EPILEPSY RESEARCH
    
    E. Perucca et al., "Assessing risk to benefit ratio in antiepileptic drug therapy", EPILEPSY R, 41(2), 2000, pp. 107-139
18. Parmeggiani, L; Belmonte, A; Ferrari, AR; Perucca, E; Guerrini, R
    Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: An open, prospective, long-term study
    JOURNAL OF CHILD NEUROLOGY
    
    L. Parmeggiani et al., "Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: An open, prospective, long-term study", J CHILD NEU, 15(10), 2000, pp. 671-674
19. Perucca, E
    Antiepileptic drugs
    SIDE EFFECTS OF DRUGS ANNUAL 23
    
    E. Perucca, "Antiepileptic drugs", SIDE EFFECT, 23, 2000, pp. 83-95
20. Perucca, E
    Is there a role for therapeutic drug monitoring of new anticonvulsants?
    CLINICAL PHARMACOKINETICS
    
    E. Perucca, "Is there a role for therapeutic drug monitoring of new anticonvulsants?", CLIN PHARMA, 38(3), 2000, pp. 191-204
21. Spina, E; Avenoso, A; Facciola, G; Salemi, M; Scordo, MG; Giacobello, T; Madia, AG; Perucca, E
    Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate
    THERAPEUTIC DRUG MONITORING
    
    E. Spina et al., "Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate", THER DRUG M, 22(4), 2000, pp. 481-485
22. Jannuzzi, G; Fattore, C; Gatti, G; Bartoli, A; Perucca, E; Cian, P; Monaco, F
    Untitled - Reply
    EPILEPSIA
    
    G. Jannuzzi et al., "Untitled - Reply", EPILEPSIA, 41(7), 2000, pp. 919-920
23. Jannuzzi, G; Cian, P; Fattore, C; Gatti, G; Bartoli, A; Monaco, F; Perucca, E
    A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy
    EPILEPSIA
    
    G. Jannuzzi et al., "A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy", EPILEPSIA, 41(2), 2000, pp. 222-230
24. Piccinelli, P; Borgatti, R; Perucca, E; Tofani, A; Donati, G; Balottin, U
    Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria
    EPILEPSIA
    
    P. Piccinelli et al., "Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria", EPILEPSIA, 41(11), 2000, pp. 1485-1488
25. Heaney, DC; Shorvon, SD; Sander, JWAS; Boon, P; Komarek, V; Marusic, P; Dravet, C; Perucca, E; Majkowski, J; Lima, JL; Arroyo, S; Tomson, T; Ried, S; van Donselaar, C; Eskazan, E; Peeters, P; Carita, P; Tjong-a-Hung, I; Myon, E; Taieb, C
    Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries
    EPILEPSIA
    
    D.C. Heaney et al., "Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries", EPILEPSIA, 41, 2000, pp. S37-S44
26. Spina, E; Avenoso, A; Facciola, G; Scordo, MG; Ancione, M; Madia, AG; Ventimiglia, A; Perucca, E
    Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics
    PSYCHOPHARMACOLOGY
    
    E. Spina et al., "Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics", PSYCHOPHAR, 148(1), 2000, pp. 83-89
27. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
    Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
    EPILEPSY RESEARCH
    
    M. Bialer et al., "Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)", EPILEPSY R, 34(1), 1999, pp. 1-41
28. Perucca, E; Tomson, T
    Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications
    EPILEPSY RESEARCH
    
    E. Perucca e T. Tomson, "Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications", EPILEPSY R, 33(2-3), 1999, pp. 247-262
29. Guerrini, R; Belmonte, A; Parmeggiani, L; Perucca, E
    Myoclonic status epilepticus following high-dosage lamotrigine therapy
    BRAIN & DEVELOPMENT
    
    R. Guerrini et al., "Myoclonic status epilepticus following high-dosage lamotrigine therapy", BRAIN DEVEL, 21(6), 1999, pp. 420-424
30. Dong, SX; Ring, ZZ; Xiao, WZ; Shu, CC; Fattore, C; Gatti, G; D'Urso, S; Perucca, E
    Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    S.X. Dong et al., "Possible enhancement of the first-pass metabolism of phenacetin by ingestion of grape juice in Chinese subjects", BR J CL PH, 48(4), 1999, pp. 638-640
31. Perucca, E
    The spectrum of the new antiepileptic drugs
    ACTA NEUROLOGICA BELGICA
    
    E. Perucca, "The spectrum of the new antiepileptic drugs", ACT NEUR BE, 99(4), 1999, pp. 231-238
32. Facciola, G; Avenoso, A; Scordo, MG; Madia, AG; Ventimiglia, A; Perucca, E; Spina, E
    Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders
    THERAPEUTIC DRUG MONITORING
    
    G. Facciola et al., "Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders", THER DRUG M, 21(3), 1999, pp. 341-345
33. Perucca, E
    Drugs under clinical trial
    ANTIEPILEPTIC DRUGS
    
    E. Perucca, "Drugs under clinical trial", HANDB EXP P, 138, 1999, pp. 515-551
34. Pisani, F; Oteri, G; Russo, MF; Di Perri, R; Perucca, E; Richens, A
    The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
    EPILEPSIA
    
    F. Pisani et al., "The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction", EPILEPSIA, 40(8), 1999, pp. 1141-1146
35. Fattore, C; Cipolla, G; Gatti, G; Limido, GL; Sturm, Y; Bernasconi, C; Perucca, E
    Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women
    EPILEPSIA
    
    C. Fattore et al., "Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women", EPILEPSIA, 40(6), 1999, pp. 783-787
36. Perucca, E
    The clinical pharmacokinetics of the new antiepileptic drugs
    EPILEPSIA
    
    E. Perucca, "The clinical pharmacokinetics of the new antiepileptic drugs", EPILEPSIA, 40, 1999, pp. S7-S13
37. Volosov, A; Sun, XD; Perucca, E; Yagen, B; Sintov, A; Perucca, E; Yagen, B; Sintov, A; Bialer, M
    Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects
    CLINICAL PHARMACOLOGY & THERAPEUTICS
    
    A. Volosov et al., "Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects", CLIN PHARM, 66(6), 1999, pp. 547-553
38. FATTORE C; CIPOLLA G; GATTI G; BARTOLI A; ORTICELLI G; PICOLLO R; MILLERIOUX L; CIOTTOLI GB; PERUCCA E
    PHARMACOKINETIC INTERACTIONS BETWEEN THEOPHYLLINE AND PRULIFLOXACIN IN HEALTHY-VOLUNTEERS
    Clinical drug investigation
    
    C. Fattore et al., "PHARMACOKINETIC INTERACTIONS BETWEEN THEOPHYLLINE AND PRULIFLOXACIN IN HEALTHY-VOLUNTEERS", Clinical drug investigation, 16(5), 1998, pp. 387-392
39. PERUCCA E
    PHARMACORESISTANCE IN EPILEPSY - HOW SHOULD IT BE DEFINED
    CNS drugs
    
    E. Perucca, "PHARMACORESISTANCE IN EPILEPSY - HOW SHOULD IT BE DEFINED", CNS drugs, 10(3), 1998, pp. 171-179
40. Baldy-Moulinier, M; Covanis, A; D'Urso, S; Eskazan, E; Fattore, C; Gatti, G; Herranz, JL; Ibrahim, S; Khalifa, A; Mrabet, A; Neufeld, MY; Perucca, E
    Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
    
    M. Baldy-Moulinier et al., "Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey", SEIZURE-E J, 7(6), 1998, pp. 513-520
41. Perucca, E
    Antiepileptic drugs
    SIDE EFFECTS OF DRUGS ANNUAL 21
    
    E. Perucca, "Antiepileptic drugs", SIDE EFFECT, 21, 1998, pp. 66-84
42. SPINA E; AVENOSO A; FACCIOLA G; FABRAZZO M; MONTELEONE P; MAJ M; PERUCCA E; CAPUTI AP
    EFFECT OF FLUOXETINE ON THE PLASMA-CONCENTRATIONS OF CLOZAPINE AND ITS MAJOR METABOLITES IN PATIENTS WITH SCHIZOPHRENIA
    International clinical psychopharmacology
    
    E. Spina et al., "EFFECT OF FLUOXETINE ON THE PLASMA-CONCENTRATIONS OF CLOZAPINE AND ITS MAJOR METABOLITES IN PATIENTS WITH SCHIZOPHRENIA", International clinical psychopharmacology, 13(3), 1998, pp. 141-145
43. FACCIOLA G; AVENOSO A; SPINA E; PERUCCA E
    INDUCING EFFECT OF PHENOBARBITAL ON CLOZAPINE METABOLISM IN PATIENTS WITH CHRONIC-SCHIZOPHRENIA
    Therapeutic drug monitoring
    
    G. Facciola et al., "INDUCING EFFECT OF PHENOBARBITAL ON CLOZAPINE METABOLISM IN PATIENTS WITH CHRONIC-SCHIZOPHRENIA", Therapeutic drug monitoring, 20(6), 1998, pp. 628-630
44. DONG SX; PING ZZ; XIAO WZ; SHU CC; BARTOLI A; GATTI G; DURSO S; PERUCCA E
    EFFECT OF ACTIVE AND PASSIVE CIGARETTE-SMOKING ON CYP1A2-MEDIATED PHENACETIN DISPOSITION IN CHINESE SUBJECTS
    Therapeutic drug monitoring
    
    S.X. Dong et al., "EFFECT OF ACTIVE AND PASSIVE CIGARETTE-SMOKING ON CYP1A2-MEDIATED PHENACETIN DISPOSITION IN CHINESE SUBJECTS", Therapeutic drug monitoring, 20(4), 1998, pp. 371-375
45. ZUCCARO P; PACIFICI R; ALTIERI I; AVENOSO A; PELLEGRINI M; SPINA E; PERUCCA E; PICHINI S
    ISSUES IN METHODOLOGY AND APPLICATIONS FOR THERAPEUTIC DRUG-MONITORING OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS
    Therapeutic drug monitoring
    
    P. Zuccaro et al., "ISSUES IN METHODOLOGY AND APPLICATIONS FOR THERAPEUTIC DRUG-MONITORING OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS", Therapeutic drug monitoring, 20(1), 1998, pp. 20-24
46. BIALER M; LEVY RH; PERUCCA E
    DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE
    Therapeutic drug monitoring
    
    M. Bialer et al., "DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE", Therapeutic drug monitoring, 20(1), 1998, pp. 56-59
47. PERUCCA E
    INNOVATIVE MONOTHERAPY TRIAL DESIGNS FOR THE ASSESSMENT OF ANTIEPILEPTIC DRUGS - A CRITICAL-APPRAISAL
    European Journal of Clinical Pharmacology
    
    E. Perucca, "INNOVATIVE MONOTHERAPY TRIAL DESIGNS FOR THE ASSESSMENT OF ANTIEPILEPTIC DRUGS - A CRITICAL-APPRAISAL", European Journal of Clinical Pharmacology, 54(1), 1998, pp. 1-5
48. BAKER GA; CAMFIELD C; CAMFIELD P; CRAMER JA; ELGER CE; JOHNSON AL; DASILVA AM; MEINARDI H; MUNARI C; PERUCCA E; THORBECKE R
    COMMISSION ON OUTCOME MEASUREMENT IN EPILEPSY, 1994-1997 - FINAL REPORT
    Epilepsia
    
    G.A. Baker et al., "COMMISSION ON OUTCOME MEASUREMENT IN EPILEPSY, 1994-1997 - FINAL REPORT", Epilepsia, 39(2), 1998, pp. 213-231
49. PERUCCA E; GRAM L; AVANZINI G; DULAC O
    ANTIEPILEPTIC DRUGS AS A CAUSE OF WORSENING SEIZURES
    Epilepsia
    
    E. Perucca et al., "ANTIEPILEPTIC DRUGS AS A CAUSE OF WORSENING SEIZURES", Epilepsia, 39(1), 1998, pp. 5-17
50. GUERRINI R; BELMONTE A; CANAPICCHI R; CASALINI C; PERUCCA E
    REVERSIBLE PSEUDOATROPHY OF THE BRAIN AND MENTAL DETERIORATION ASSOCIATED WITH VALPROATE TREATMENT
    Epilepsia
    
    R. Guerrini et al., "REVERSIBLE PSEUDOATROPHY OF THE BRAIN AND MENTAL DETERIORATION ASSOCIATED WITH VALPROATE TREATMENT", Epilepsia, 39(1), 1998, pp. 27-32
51. DERIL GM; MORATTI R; PERUCCA E
    TOTAL AND NON-PROTEIN-BOUND FRACTIONS OF 3,4-DIHYDROXYPHENYLALANINE
    Clinical chemistry
    
    G.M. Deril et al., "TOTAL AND NON-PROTEIN-BOUND FRACTIONS OF 3,4-DIHYDROXYPHENYLALANINE", Clinical chemistry, 44(4), 1998, pp. 895-895
52. PERUCCA E
    A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG
    Pharmacological research
    
    E. Perucca, "A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG", Pharmacological research, 35(4), 1997, pp. 241-256
53. AVENOSO A; SPINA E; CAMPO G; FACCIOLA G; FERLITO M; ZUCCARO P; PERUCCA E; CAPUTI AP
    INTERACTION BETWEEN FLUOXETINE AND HALOPERIDOL - PHARMACOKINETIC AND CLINICAL IMPLICATIONS
    Pharmacological research
    
    A. Avenoso et al., "INTERACTION BETWEEN FLUOXETINE AND HALOPERIDOL - PHARMACOKINETIC AND CLINICAL IMPLICATIONS", Pharmacological research, 35(4), 1997, pp. 335-339
54. PERUCCA E
    EVALUATION OF DRUG-TREATMENT OUTCOME IN EPILEPSY - A CLINICAL PERSPECTIVE
    Pharmacy world & science
    
    E. Perucca, "EVALUATION OF DRUG-TREATMENT OUTCOME IN EPILEPSY - A CLINICAL PERSPECTIVE", Pharmacy world & science, 19(5), 1997, pp. 217-222
55. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)
    Epilepsy research
    
    M. Bialer et al., "CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)", Epilepsy research, 26(3), 1997, pp. 465-465
56. PERUCCA E; MARCHIONI E; SORAGNA D; SAVOLDI F
    FLUOXETINE-INDUCED MOVEMENT-DISORDERS AND DEFICIENT CYP2D6 ENZYME-ACTIVITY
    Movement disorders
    
    E. Perucca et al., "FLUOXETINE-INDUCED MOVEMENT-DISORDERS AND DEFICIENT CYP2D6 ENZYME-ACTIVITY", Movement disorders, 12(4), 1997, pp. 624-624
57. SPINA E; AVENOSO A; CAMPO GM; SCORDO MG; CAPUTI AP; PERUCCA E
    EFFECT OF KETOCONAZOLE ON THE PHARMACOKINETICS OF IMIPRAMINE AND DESIPRAMINE IN HEALTHY-SUBJECTS
    British journal of clinical pharmacology
    
    E. Spina et al., "EFFECT OF KETOCONAZOLE ON THE PHARMACOKINETICS OF IMIPRAMINE AND DESIPRAMINE IN HEALTHY-SUBJECTS", British journal of clinical pharmacology, 43(3), 1997, pp. 315-318
58. SPINA E; ARENA D; SCORDO MG; FAZIO A; PISANI F; PERUCCA E
    ELEVATION OF PLASMA CARBAMAZEPINE CONCENTRATIONS BY KETOCONAZOLE IN PATIENTS WITH EPILEPSY
    Therapeutic drug monitoring
    
    E. Spina et al., "ELEVATION OF PLASMA CARBAMAZEPINE CONCENTRATIONS BY KETOCONAZOLE IN PATIENTS WITH EPILEPSY", Therapeutic drug monitoring, 19(5), 1997, pp. 535-538
59. BARTOLI A; GUERRINI R; BELMONTE A; ALESSANDRI MG; GATTI G; PERUCCA E
    THE INFLUENCE OF DOSAGE, AGE, AND COMEDICATION ON STEADY-STATE PLASMALAMOTRIGINE CONCENTRATIONS IN EPILEPTIC CHILDREN - A PROSPECTIVE-STUDY WITH PRELIMINARY ASSESSMENT OF CORRELATIONS WITH CLINICAL-RESPONSE
    Therapeutic drug monitoring
    
    A. Bartoli et al., "THE INFLUENCE OF DOSAGE, AGE, AND COMEDICATION ON STEADY-STATE PLASMALAMOTRIGINE CONCENTRATIONS IN EPILEPTIC CHILDREN - A PROSPECTIVE-STUDY WITH PRELIMINARY ASSESSMENT OF CORRELATIONS WITH CLINICAL-RESPONSE", Therapeutic drug monitoring, 19(3), 1997, pp. 252-260
60. SPINA E; GITTO C; AVENOSO A; CAMPO GM; CAPUTI AP; PERUCCA E
    RELATIONSHIP BETWEEN PLASMA DESIPRAMINE LEVELS, CYP2D6 PHENOTYPE AND CLINICAL-RESPONSE TO DESIPRAMINE - A PROSPECTIVE-STUDY
    European Journal of Clinical Pharmacology
    
    E. Spina et al., "RELATIONSHIP BETWEEN PLASMA DESIPRAMINE LEVELS, CYP2D6 PHENOTYPE AND CLINICAL-RESPONSE TO DESIPRAMINE - A PROSPECTIVE-STUDY", European Journal of Clinical Pharmacology, 51(5), 1997, pp. 395-398
61. BARTOLI A; GATTI G; CIPOLLA G; BARZAGHI N; VELIZ G; FATTORE C; MUMFORD J; PERUCCA E
    A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFECT OF VIGABATRIN ON IN-VIVO PARAMETERS OF HEPATIC-MICROSOMAL ENZYME-INDUCTION AND ON THE KINETICS OF STEROID ORAL-CONTRACEPTIVES IN HEALTHY FEMALE VOLUNTEERS
    Epilepsia
    
    A. Bartoli et al., "A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFECT OF VIGABATRIN ON IN-VIVO PARAMETERS OF HEPATIC-MICROSOMAL ENZYME-INDUCTION AND ON THE KINETICS OF STEROID ORAL-CONTRACEPTIVES IN HEALTHY FEMALE VOLUNTEERS", Epilepsia, 38(6), 1997, pp. 702-707
62. BAREL S; YAGEN B; SCHURIG V; SOBACK S; PISANI F; PERUCCA E; BIALER M
    STEREOSELECTIVE PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE IN HEALTHY-SUBJECTS AND IN PATIENTS WITH EPILEPSY
    Clinical pharmacology and therapeutics
    
    S. Barel et al., "STEREOSELECTIVE PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE IN HEALTHY-SUBJECTS AND IN PATIENTS WITH EPILEPSY", Clinical pharmacology and therapeutics, 61(4), 1997, pp. 442-449
63. PERUCCA E
    ESTABLISHED ANTIEPILEPTIC DRUGS
    Bailliere's clinical neurology
    
    E. Perucca, "ESTABLISHED ANTIEPILEPTIC DRUGS", Bailliere's clinical neurology, 5(4), 1996, pp. 693-722
64. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
    Epilepsy research
    
    M. Bialer et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE", Epilepsy research, 25(3), 1996, pp. 299-319
65. RIZZO V; MEMMI M; MORATTI R; DERIL GM; PERUCCA E
    CONCENTRATIONS OF L-DOPA IN PLASMA AND PLASMA ULTRAFILTRATES
    Journal of pharmaceutical and biomedical analysis
    
    V. Rizzo et al., "CONCENTRATIONS OF L-DOPA IN PLASMA AND PLASMA ULTRAFILTRATES", Journal of pharmaceutical and biomedical analysis, 14(8-10), 1996, pp. 1043-1046
66. TARTARA A; SARTORI I; MANNI R; GALIMBERTI CA; DIFAZIO M; PERUCCA E
    EFFICACY AND SAFETY OF TOPIRAMATE IN REFRACTORY EPILEPSY - A LONG-TERM PROSPECTIVE TRIAL
    Italian journal of neurological sciences
    
    A. Tartara et al., "EFFICACY AND SAFETY OF TOPIRAMATE IN REFRACTORY EPILEPSY - A LONG-TERM PROSPECTIVE TRIAL", Italian journal of neurological sciences, 17(6), 1996, pp. 429-432
67. SPINA E; PISANI F; PERUCCA E
    CLINICALLY SIGNIFICANT PHARMACOKINETIC DRUG-INTERACTIONS WITH CARBAMAZEPINE - AN UPDATE
    Clinical pharmacokinetics
    
    E. Spina et al., "CLINICALLY SIGNIFICANT PHARMACOKINETIC DRUG-INTERACTIONS WITH CARBAMAZEPINE - AN UPDATE", Clinical pharmacokinetics, 31(3), 1996, pp. 198-214
68. PERUCCA E; BIALER M
    THE CLINICAL PHARMACOKINETICS OF THE NEWER ANTIEPILEPTIC DRUGS - FOCUS ON TOPIRAMATE, ZONISAMIDE AND TIAGABINE
    Clinical pharmacokinetics
    
    E. Perucca e M. Bialer, "THE CLINICAL PHARMACOKINETICS OF THE NEWER ANTIEPILEPTIC DRUGS - FOCUS ON TOPIRAMATE, ZONISAMIDE AND TIAGABINE", Clinical pharmacokinetics, 31(1), 1996, pp. 29-46
69. PERUCCA E
    THE NEW-GENERATION OF ANTIEPILEPTIC DRUGS - ADVANTAGES AND DISADVANTAGES
    British journal of clinical pharmacology
    
    E. Perucca, "THE NEW-GENERATION OF ANTIEPILEPTIC DRUGS - ADVANTAGES AND DISADVANTAGES", British journal of clinical pharmacology, 42(5), 1996, pp. 531-543
70. BARTOLI A; XIAODONG S; GATTI G; CIPOLLA G; MARCHISELLI R; PERUCCA E
    THE INFLUENCE OF ETHNIC FACTORS AND GENDER ON CYP1A2-MEDIATED DRUG DISPOSITION - A COMPARATIVE-STUDY IN CAUCASIAN AND CHINESE SUBJECTS USING PHENACETIN AS A MARKER SUBSTRATE
    Therapeutic drug monitoring
    
    A. Bartoli et al., "THE INFLUENCE OF ETHNIC FACTORS AND GENDER ON CYP1A2-MEDIATED DRUG DISPOSITION - A COMPARATIVE-STUDY IN CAUCASIAN AND CHINESE SUBJECTS USING PHENACETIN AS A MARKER SUBSTRATE", Therapeutic drug monitoring, 18(5), 1996, pp. 586-591
71. SPINA E; AVENOSO A; CAMPO GM; CAPUTI AP; PERUCCA E
    PHENOBARBITAL INDUCES THE 2-HYDROXYLATION OF DESIPRAMINE
    Therapeutic drug monitoring
    
    E. Spina et al., "PHENOBARBITAL INDUCES THE 2-HYDROXYLATION OF DESIPRAMINE", Therapeutic drug monitoring, 18(1), 1996, pp. 60-64
72. MARCHIONI E; PERUCCA E; SORAGNA D; BO P; MALASPINA A; FERRANDI D; ALBERGATI A; SAVOLDI F
    CHOREIFORM SYNDROME-ASSOCIATED WITH FLUOXETINE TREATMENT IN A PATIENTWITH DEFICIENT CYP2D6 ACTIVITY
    Neurology
    
    E. Marchioni et al., "CHOREIFORM SYNDROME-ASSOCIATED WITH FLUOXETINE TREATMENT IN A PATIENTWITH DEFICIENT CYP2D6 ACTIVITY", Neurology, 46(3), 1996, pp. 853-853
73. MICHELUCCI R; CIPOLLA G; PASSARELLI D; GATTI G; OCHAN M; HEINIG R; TASSINARI CA; PERUCCA E
    REDUCED PLASMA NISOLDIPINE CONCENTRATIONS IN PHENYTOIN-TREATED PATIENTS WITH EPILEPSY
    Epilepsia
    
    R. Michelucci et al., "REDUCED PLASMA NISOLDIPINE CONCENTRATIONS IN PHENYTOIN-TREATED PATIENTS WITH EPILEPSY", Epilepsia, 37(11), 1996, pp. 1107-1110
74. PERUCCA E
    PHARMACOKINETIC PROFILE OF TOPIRAMATE IN COMPARISON WITH OTHER NEW ANTIEPILEPTIC DRUGS
    Epilepsia
    
    E. Perucca, "PHARMACOKINETIC PROFILE OF TOPIRAMATE IN COMPARISON WITH OTHER NEW ANTIEPILEPTIC DRUGS", Epilepsia, 37, 1996, pp. 8-13
75. STABLES JP; BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE
    Epilepsy research
    
    J.P. Stables et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE", Epilepsy research, 22(3), 1995, pp. 235-246
76. PERUCCA E; POITOU P; PIFFERI G
    COMPARATIVE PHARMACOKINETICS AND BIOAVAILABILITY OF 2 ORAL FORMULATIONS OF THIOCOLCHICOSIDE, A GABA-MIMETIC MUSCLE-RELAXANT DRUG, IN NORMALVOLUNTEERS
    European journal of drug metabolism and pharmacokinetics
    
    E. Perucca et al., "COMPARATIVE PHARMACOKINETICS AND BIOAVAILABILITY OF 2 ORAL FORMULATIONS OF THIOCOLCHICOSIDE, A GABA-MIMETIC MUSCLE-RELAXANT DRUG, IN NORMALVOLUNTEERS", European journal of drug metabolism and pharmacokinetics, 20(4), 1995, pp. 301-305
77. PIFFERI G; PERUCCA E
    THE COST-BENEFIT RATIO OF ENANTIOMERIC DRUGS
    European journal of drug metabolism and pharmacokinetics
    
    G. Pifferi e E. Perucca, "THE COST-BENEFIT RATIO OF ENANTIOMERIC DRUGS", European journal of drug metabolism and pharmacokinetics, 20(1), 1995, pp. 15-25
78. PERUCCA E
    RATIONAL DRUG SELECTION IN ADULTS
    Epilepsia
    
    E. Perucca, "RATIONAL DRUG SELECTION IN ADULTS", Epilepsia, 36, 1995, pp. 89-89
79. TARTARA A; SARTORI I; MANNI R; GALIMBERTI CA; DIFAZIO M; PERUCCA E
    ADD-ON TRIAL OF TOPIRAMATE IN REFRACTORY EPILEPSY
    Epilepsia
    
    A. Tartara et al., "ADD-ON TRIAL OF TOPIRAMATE IN REFRACTORY EPILEPSY", Epilepsia, 36, 1995, pp. 150-151
80. BARTOLI A; GATTI G; BARZAGHI N; CIPOLLA G; VELIZ G; MUMFORD JP; PERUCCA E
    VIGABATRIN DOES NOT AFFECT IN-VIVO PARAMETERS OF ENZYME-INDUCTION IN HUMANS
    Epilepsia
    
    A. Bartoli et al., "VIGABATRIN DOES NOT AFFECT IN-VIVO PARAMETERS OF ENZYME-INDUCTION IN HUMANS", Epilepsia, 36, 1995, pp. 162-162
81. PERUCCA E
    SHOULD WIDESPREAD COMPASSIONATE USE BEFORE REGISTRATION BE ALLOWED - A CONTRARY VIEW
    Epilepsia
    
    E. Perucca, "SHOULD WIDESPREAD COMPASSIONATE USE BEFORE REGISTRATION BE ALLOWED - A CONTRARY VIEW", Epilepsia, 36, 1995, pp. 217-217
82. PISANI F; OTERI G; RUSSO M; TRIO R; DIPERRI R; PERUCCA E; RICHENS A
    EFFECTS OF LAMOTRIGINE-VALPROATE COMEDICATION ON SEIZURE FREQUENCY AND UPPER-LIMB TREMOR - A PHARMACODYNAMIC INTERACTION
    Epilepsia
    
    F. Pisani et al., "EFFECTS OF LAMOTRIGINE-VALPROATE COMEDICATION ON SEIZURE FREQUENCY AND UPPER-LIMB TREMOR - A PHARMACODYNAMIC INTERACTION", Epilepsia, 36, 1995, pp. 264-264
83. BEGHI E; PERUCCA E
    THE MANAGEMENT OF EPILEPSY IN THE 1990S - ACQUISITIONS, UNCERTAINTIESAND PRIORITIES FOR FUTURE-RESEARCH
    Drugs
    
    E. Beghi e E. Perucca, "THE MANAGEMENT OF EPILEPSY IN THE 1990S - ACQUISITIONS, UNCERTAINTIESAND PRIORITIES FOR FUTURE-RESEARCH", Drugs, 49(5), 1995, pp. 680-694
84. PERUCCA E
    PHARMACOLOGICAL PRINCIPLES AS A BASIS FOR POLYTHERAPY
    Acta neurologica Scandinavica
    
    E. Perucca, "PHARMACOLOGICAL PRINCIPLES AS A BASIS FOR POLYTHERAPY", Acta neurologica Scandinavica, 92, 1995, pp. 31-34
85. SILFVENIUS H; HALASZ P; ROSCISZEWSKA; HAUSER WA; STELMASIAK; SCHMIDT D; PITKANEN A; MATTSON RH; MARROSU; RICHENS A; PERUCCA E; YLINEN A; DEBITTENCOURT PRM
    THE RATIONAL MANAGEMENT OF EPILEPSY THROUGH GREATER UNDERSTANDING OF THE DISEASE - DISCUSSION
    Acta neurologica Scandinavica
    
    H. Silfvenius et al., "THE RATIONAL MANAGEMENT OF EPILEPSY THROUGH GREATER UNDERSTANDING OF THE DISEASE - DISCUSSION", Acta neurologica Scandinavica, 92, 1995, pp. 51-55
86. SPINA E; AVENOSO A; CAMPO GM; CAPUTI AP; PERUCCA E
    THE EFFECT OF CARBAMAZEPINE ON THE 2-HYDROXYLATION OF DESIPRAMINE
    Psychopharmacology
    
    E. Spina et al., "THE EFFECT OF CARBAMAZEPINE ON THE 2-HYDROXYLATION OF DESIPRAMINE", Psychopharmacology, 117(4), 1995, pp. 413-416
87. SPINA E; PERUCCA E
    NEWER AND OLDER ANTIDEPRESSANTS - A COMPARATIVE REVIEW OF DRUG-INTERACTIONS
    CNS DRUGS
    
    E. Spina e E. Perucca, "NEWER AND OLDER ANTIDEPRESSANTS - A COMPARATIVE REVIEW OF DRUG-INTERACTIONS", CNS DRUGS, 2(6), 1994, pp. 479-497
88. SPINA E; CAMPO GM; AVENOSO A; CAPUTI AP; ZUCCARO P; PACIFICI R; GATTI G; STRADA G; BARTOLI A; PERUCCA E
    CYP2D6-RELATED OXIDATION POLYMORPHISM IN ITALY
    Pharmacological research
    
    E. Spina et al., "CYP2D6-RELATED OXIDATION POLYMORPHISM IN ITALY", Pharmacological research, 29(3), 1994, pp. 281-289
89. GATTI G; PERUCCA E
    PLASMA-CONCENTRATIONS OF FREE AND CONJUGATED SILYBIN AFTER ORAL INTAKE OF A SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX (SILIPIDE) IN HEALTHY-VOLUNTEERS
    International journal of clinical pharmacology and therapeutics
    
    G. Gatti e E. Perucca, "PLASMA-CONCENTRATIONS OF FREE AND CONJUGATED SILYBIN AFTER ORAL INTAKE OF A SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX (SILIPIDE) IN HEALTHY-VOLUNTEERS", International journal of clinical pharmacology and therapeutics, 32(11), 1994, pp. 614-617
90. PISANI F; XIAO B; FAZIO A; SPINA E; PERUCCA E; TOMSON T
    SINGLE-DOSE PHARMACOKINETICS OF CARBAMAZEPINE-10,11-EPOXIDE IN PATIENTS ON LAMOTRIGINE MONOTHERAPY
    Epilepsy research
    
    F. Pisani et al., "SINGLE-DOSE PHARMACOKINETICS OF CARBAMAZEPINE-10,11-EPOXIDE IN PATIENTS ON LAMOTRIGINE MONOTHERAPY", Epilepsy research, 19(3), 1994, pp. 245-248
91. CORASANITI MT; GATTI G; CREMA F; ATTARDOPARRINELLO G; BARZAGHI N; PERUCCA E
    THE DISPOSITION OF THEOPHYLLINE IN PATIENTS WITH LUNG AND BREAST-CANCER
    Drugs under experimental and clinical research
    
    M.T. Corasaniti et al., "THE DISPOSITION OF THEOPHYLLINE IN PATIENTS WITH LUNG AND BREAST-CANCER", Drugs under experimental and clinical research, 20(3), 1994, pp. 115-120
92. SCHANDALIK R; PERUCCA E
    PHARMACOKINETICS OF SILYBIN FOLLOWING ORAL-ADMINISTRATION OF SILIPIDEIN PATIENTS WITH EXTRAHEPATIC BILIARY OBSTRUCTION
    Drugs under experimental and clinical research
    
    R. Schandalik e E. Perucca, "PHARMACOKINETICS OF SILYBIN FOLLOWING ORAL-ADMINISTRATION OF SILIPIDEIN PATIENTS WITH EXTRAHEPATIC BILIARY OBSTRUCTION", Drugs under experimental and clinical research, 20(1), 1994, pp. 37-42
93. PERUCCA E; GATTI G; SPINA E
    CLINICAL PHARMACOKINETICS OF FLUVOXAMINE
    Clinical pharmacokinetics
    
    E. Perucca et al., "CLINICAL PHARMACOKINETICS OF FLUVOXAMINE", Clinical pharmacokinetics, 27(3), 1994, pp. 175-190
94. SPINA E; AVENOSO A; CAMPO GM; CAPUTI AP; PERUCCA E
    DECREASED PLASMA-CONCENTRATIONS OF IMIPRAMINE AND DESIPRAMINE FOLLOWING CHOLESTYRAMINE INTAKE IN DEPRESSED-PATIENTS
    Therapeutic drug monitoring
    
    E. Spina et al., "DECREASED PLASMA-CONCENTRATIONS OF IMIPRAMINE AND DESIPRAMINE FOLLOWING CHOLESTYRAMINE INTAKE IN DEPRESSED-PATIENTS", Therapeutic drug monitoring, 16(4), 1994, pp. 432-434
95. XIAODONG S; GATTI G; BARTOLI A; CIPOLLA G; CREMA F; PERUCCA E
    OMEPRAZOLE DOES NOT ENHANCE THE METABOLISM OF PHENACETIN, A MARKER OFCYP1A2 ACTIVITY, IN HEALTHY-VOLUNTEERS
    Therapeutic drug monitoring
    
    S. Xiaodong et al., "OMEPRAZOLE DOES NOT ENHANCE THE METABOLISM OF PHENACETIN, A MARKER OFCYP1A2 ACTIVITY, IN HEALTHY-VOLUNTEERS", Therapeutic drug monitoring, 16(3), 1994, pp. 248-250
96. GATTI G; BARTOLI A; BERTIN D; STROLINBENEDETTI M; PERUCCA E
    PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOLLOWING SINGLE AND MULTIPLE DOSES OF ROLAFAGREL, A NOVEL INHIBITOR OF THROMBOXANE SYNTHASE, IN NORMAL VOLUNTEERS
    European Journal of Clinical Pharmacology
    
    G. Gatti et al., "PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOLLOWING SINGLE AND MULTIPLE DOSES OF ROLAFAGREL, A NOVEL INHIBITOR OF THROMBOXANE SYNTHASE, IN NORMAL VOLUNTEERS", European Journal of Clinical Pharmacology, 47(3), 1994, pp. 275-280
97. GATTI G; BARTOLI A; BERTIN D; STROLINBENEDETTI M; PERUCCA E
    PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOLLOWING SINGLE AND MULTIPLE DOSES OF ROLAFAGREL, A NOVEL INHIBITOR OF THROMBOXANE SYNTHASE, IN NORMAL VOLUNTEERS
    European Journal of Clinical Pharmacology
    
    G. Gatti et al., "PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES FOLLOWING SINGLE AND MULTIPLE DOSES OF ROLAFAGREL, A NOVEL INHIBITOR OF THROMBOXANE SYNTHASE, IN NORMAL VOLUNTEERS", European Journal of Clinical Pharmacology, 47(3), 1994, pp. 275-280
98. ADAMOLEKUM B; CARPIO A; CARVALHO P; GARCIAPEDROSA F; MAHESHWARI MC; MEINARDI H; ORDINARIO A; OSUNTOKUM B; PERUCCA E; PRICE RW; ROMAN G; SHAKIR RA; SOTELO J; SPINAFRANCA A; TAKAYANAGUI O; DEBITTENCOURT PRM; BHARUCHA N
    RELATIONSHIP BETWEEN EPILEPSY AND TROPICAL DISEASES
    Epilepsia
    
    B. Adamolekum et al., "RELATIONSHIP BETWEEN EPILEPSY AND TROPICAL DISEASES", Epilepsia, 35(1), 1994, pp. 89-93
99. PERUCCA E; GATTI G; CIPOLLA G; SPINA E; BAREL S; SOBACK S; GIPS M; BIALER M
    INHIBITION OF DIAZEPAM METABOLISM BY FLUVOXAMINE - A PHARMACOKINETIC STUDY IN NORMAL VOLUNTEERS
    Clinical pharmacology and therapeutics
    
    E. Perucca et al., "INHIBITION OF DIAZEPAM METABOLISM BY FLUVOXAMINE - A PHARMACOKINETIC STUDY IN NORMAL VOLUNTEERS", Clinical pharmacology and therapeutics, 56(5), 1994, pp. 471-476
100. PISANI F; FAZIO A; OTERI G; ARTESI C; XIAO B; PERUCCA E; DIPERRI R
     EFFECTS OF THE ANTIDEPRESSANT DRUG VILOXAZINE ON OXCARBAZEPINE AND ITS HYDROXYLATED METABOLITES IN PATIENTS WITH EPILEPSY
     Acta neurologica Scandinavica
     
     F. Pisani et al., "EFFECTS OF THE ANTIDEPRESSANT DRUG VILOXAZINE ON OXCARBAZEPINE AND ITS HYDROXYLATED METABOLITES IN PATIENTS WITH EPILEPSY", Acta neurologica Scandinavica, 90(2), 1994, pp. 130-132